EV-TRACK

Search > Results

You searched for: EV210220 (EV-TRACK ID)

Showing 1 - 6 of 6

Results list Study Tree

Details	EV-TRACK ID	Experiment nr.	Species	Sample type	Separation protocol	First author	Year	EV-METRIC
	EV210220	1/6	Homo sapiens	Blood plasma	DG (d)(U)C ExoQuick	Ermini, Leonardo	2017	45%
Study summary Full title A Single Sphingomyelin Species Promotes Exosomal Release of Endoglin into the Maternal Circulation in Preeclampsia All authors Leonardo Ermini, Jonathan Ausman, Megan Melland-Smith, Behzad Yeganeh, Alessandro Rolfo, Michael L Litvack, Tullia Todros, Michelle Letarte, Martin Post 10 11 , Isabella Caniggia 12 Journal Sci Rep Abstract Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a (show more...)Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a short form of the auxillary TGF-beta (TGFB) receptor endoglin (sENG). Until now, its release and functionality in PE remains poorly understood. Here we show that ENG selectively interacts with sphingomyelin(SM)-18:0 which promotes its clustering with metalloproteinase 14 (MMP14) in SM-18:0 enriched lipid rafts of the apical syncytial membranes from PE placenta where ENG is cleaved by MMP14 into sENG. The SM-18:0 enriched lipid rafts also contain type 1 and 2 TGFB receptors (TGFBR1 and TGFBR2), but not soluble fms-like tyrosine kinase 1 (sFLT1), another protein secreted in excess in the circulation of women with PE. The truncated ENG is then released into the maternal circulation via SM-18:0 enriched exosomes together with TGFBR1 and 2. Such an exosomal TGFB receptor complex could be functionally active and block the vascular effects of TGFB in the circulation of PE women. (hide) EV-METRIC 45% (78th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Blood plasma Sample origin Healthy pregnant Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture DG (d)(U)C Commercial method Protein markers EV: CD63/ PLAP/ sENG/ sFLT-1 non-EV: None Proteomics no EV density (g/ml) * Show all info Study aim Function Sample Species Homo sapiens Sample Type Blood plasma Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Equal to or above 150,000 g Pelleting performed Yes Pelleting: time(min) 1200 Pelleting: rotor type TLA-55 Pelleting: speed (g) 200000 Density gradient Type Discontinuous Number of initial discontinuous layers Not specified Lowest density fraction 0.25M Highest density fraction 2.5M Total gradient volume, incl. sample (mL) Not specified Sample volume (mL) Not spec Orientation Not specified Rotor type TLA-100 Speed (g) 110000 Duration (min) 1200 Fraction volume (mL) 10 fractions, 0.3mL per fraction Fraction processing None Commercial kit ExoQuick Characterization: Protein analysis Protein Concentration Method Not determined Western Blot Antibody details provided? No Detected EV-associated proteins CD63/ PLAP Not detected EV-associated proteins sENG/ sFLT-1 Characterization: Lipid analysis Lipi Characterization: Particle analysis NTA Report type Size range/distribution Reported size (nm) 100-400 EM EM-type Transmission-EM Image type Close-up Report size (nm) 100nm

	EV210220	2/6	Homo sapiens	Blood plasma	DG (d)(U)C ExoQuick Immunoaffinity capture	Ermini, Leonardo	2017	45%
Study summary Full title A Single Sphingomyelin Species Promotes Exosomal Release of Endoglin into the Maternal Circulation in Preeclampsia All authors Leonardo Ermini, Jonathan Ausman, Megan Melland-Smith, Behzad Yeganeh, Alessandro Rolfo, Michael L Litvack, Tullia Todros, Michelle Letarte, Martin Post 10 11 , Isabella Caniggia 12 Journal Sci Rep Abstract Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a (show more...)Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a short form of the auxillary TGF-beta (TGFB) receptor endoglin (sENG). Until now, its release and functionality in PE remains poorly understood. Here we show that ENG selectively interacts with sphingomyelin(SM)-18:0 which promotes its clustering with metalloproteinase 14 (MMP14) in SM-18:0 enriched lipid rafts of the apical syncytial membranes from PE placenta where ENG is cleaved by MMP14 into sENG. The SM-18:0 enriched lipid rafts also contain type 1 and 2 TGFB receptors (TGFBR1 and TGFBR2), but not soluble fms-like tyrosine kinase 1 (sFLT1), another protein secreted in excess in the circulation of women with PE. The truncated ENG is then released into the maternal circulation via SM-18:0 enriched exosomes together with TGFBR1 and 2. Such an exosomal TGFB receptor complex could be functionally active and block the vascular effects of TGFB in the circulation of PE women. (hide) EV-METRIC 45% (78th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Blood plasma Sample origin Healthy pregnant Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture DG (d)(U)C Commercial method Immunoaffinity capture Protein markers EV: CD63/ TGFBR1/ TGFBR2/ sENG non-EV: None Proteomics no EV density (g/ml) * Show all info Study aim Function Sample Species Homo sapiens Sample Type Blood plasma Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Equal to or above 150,000 g Pelleting performed Yes Pelleting: time(min) 1200 Pelleting: rotor type TLA-55 Pelleting: speed (g) 200000 Density gradient Type Discontinuous Number of initial discontinuous layers Not specified Lowest density fraction 0.25M Highest density fraction 2.5M Total gradient volume, incl. sample (mL) Not specified Sample volume (mL) Not spec Orientation Not specified Rotor type TLA-100 Speed (g) 110000 Duration (min) 1200 Fraction volume (mL) 10 fractions, 0.3mL per fraction Fraction processing None Commercial kit ExoQuick Immunoaffinity capture Selected surface protein(s) PLAP Other Name other separation method Immunoaffinity capture Characterization: Protein analysis Protein Concentration Method Not determined Western Blot Antibody details provided? No Detected EV-associated proteins CD63/ TGFBR1/ TGFBR2 Not detected EV-associated proteins sENG Characterization: Lipid analysis Lipi Characterization: Particle analysis None

	EV210220	3/6	Homo sapiens	Blood plasma	DG (d)(U)C ExoQuick	Ermini, Leonardo	2017	45%
Study summary Full title A Single Sphingomyelin Species Promotes Exosomal Release of Endoglin into the Maternal Circulation in Preeclampsia All authors Leonardo Ermini, Jonathan Ausman, Megan Melland-Smith, Behzad Yeganeh, Alessandro Rolfo, Michael L Litvack, Tullia Todros, Michelle Letarte, Martin Post 10 11 , Isabella Caniggia 12 Journal Sci Rep Abstract Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a (show more...)Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a short form of the auxillary TGF-beta (TGFB) receptor endoglin (sENG). Until now, its release and functionality in PE remains poorly understood. Here we show that ENG selectively interacts with sphingomyelin(SM)-18:0 which promotes its clustering with metalloproteinase 14 (MMP14) in SM-18:0 enriched lipid rafts of the apical syncytial membranes from PE placenta where ENG is cleaved by MMP14 into sENG. The SM-18:0 enriched lipid rafts also contain type 1 and 2 TGFB receptors (TGFBR1 and TGFBR2), but not soluble fms-like tyrosine kinase 1 (sFLT1), another protein secreted in excess in the circulation of women with PE. The truncated ENG is then released into the maternal circulation via SM-18:0 enriched exosomes together with TGFBR1 and 2. Such an exosomal TGFB receptor complex could be functionally active and block the vascular effects of TGFB in the circulation of PE women. (hide) EV-METRIC 45% (78th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Blood plasma Sample origin Preeclampsia Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture DG (d)(U)C Commercial method Protein markers EV: CD63/ PLAP/ sENG/ sFLT-1 non-EV: None Proteomics no EV density (g/ml) * Show all info Study aim Function Sample Species Homo sapiens Sample Type Blood plasma Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Equal to or above 150,000 g Pelleting performed Yes Pelleting: time(min) 1200 Pelleting: rotor type TLA-55 Pelleting: speed (g) 200000 Density gradient Type Discontinuous Number of initial discontinuous layers Not specified Lowest density fraction 0.25M Highest density fraction 2.5M Total gradient volume, incl. sample (mL) Not specified Sample volume (mL) Not spec Orientation Not specified Rotor type TLA-100 Speed (g) 110000 Duration (min) 1200 Fraction volume (mL) 10 fractions, 0.3mL per fraction Fraction processing None Commercial kit ExoQuick Characterization: Protein analysis Protein Concentration Method Not determined Western Blot Antibody details provided? No Detected EV-associated proteins sENG/ CD63/ PLAP Not detected EV-associated proteins sFLT-1 Flow cytometry Type of Flow cytometry Beckman Coulter Gallios 10/3 Antibody details provided? No Detected EV-associated proteins PLAP Characterization: Lipid analysis Lipi Characterization: Particle analysis NTA Report type Size range/distribution Reported size (nm) 100-400

	EV210220	4/6	Homo sapiens	Blood plasma	DG (d)(U)C ExoQuick Immunoaffinity capture	Ermini, Leonardo	2017	45%
Study summary Full title A Single Sphingomyelin Species Promotes Exosomal Release of Endoglin into the Maternal Circulation in Preeclampsia All authors Leonardo Ermini, Jonathan Ausman, Megan Melland-Smith, Behzad Yeganeh, Alessandro Rolfo, Michael L Litvack, Tullia Todros, Michelle Letarte, Martin Post 10 11 , Isabella Caniggia 12 Journal Sci Rep Abstract Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a (show more...)Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a short form of the auxillary TGF-beta (TGFB) receptor endoglin (sENG). Until now, its release and functionality in PE remains poorly understood. Here we show that ENG selectively interacts with sphingomyelin(SM)-18:0 which promotes its clustering with metalloproteinase 14 (MMP14) in SM-18:0 enriched lipid rafts of the apical syncytial membranes from PE placenta where ENG is cleaved by MMP14 into sENG. The SM-18:0 enriched lipid rafts also contain type 1 and 2 TGFB receptors (TGFBR1 and TGFBR2), but not soluble fms-like tyrosine kinase 1 (sFLT1), another protein secreted in excess in the circulation of women with PE. The truncated ENG is then released into the maternal circulation via SM-18:0 enriched exosomes together with TGFBR1 and 2. Such an exosomal TGFB receptor complex could be functionally active and block the vascular effects of TGFB in the circulation of PE women. (hide) EV-METRIC 45% (78th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Blood plasma Sample origin Preeclampsia Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture DG (d)(U)C Commercial method Immunoaffinity capture Protein markers EV: CD63/ TGFBR1/ TGFBR2/ sENG non-EV: None Proteomics no EV density (g/ml) * Show all info Study aim Function Sample Species Homo sapiens Sample Type Blood plasma Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Equal to or above 150,000 g Pelleting performed Yes Pelleting: time(min) 1200 Pelleting: rotor type TLA-55 Pelleting: speed (g) 200000 Density gradient Type Discontinuous Number of initial discontinuous layers Not specified Lowest density fraction 0.25M Highest density fraction 2.5M Total gradient volume, incl. sample (mL) Not specified Sample volume (mL) Not spec Orientation Not specified Rotor type TLA-100 Speed (g) 110000 Duration (min) 1200 Fraction volume (mL) 10 fractions, 0.3mL per fraction Fraction processing None Commercial kit ExoQuick Immunoaffinity capture Selected surface protein(s) PLAP Other Name other separation method Immunoaffinity capture Characterization: Protein analysis Protein Concentration Method Not determined Western Blot Antibody details provided? No Detected EV-associated proteins CD63/ TGFBR1/ TGFBR2/ sENG Characterization: Lipid analysis Lipi Characterization: Particle analysis None

	EV210220	5/6	Homo sapiens	Blood plasma	DG (d)(U)C ExoQuick	Ermini, Leonardo	2017	45%
Study summary Full title A Single Sphingomyelin Species Promotes Exosomal Release of Endoglin into the Maternal Circulation in Preeclampsia All authors Leonardo Ermini, Jonathan Ausman, Megan Melland-Smith, Behzad Yeganeh, Alessandro Rolfo, Michael L Litvack, Tullia Todros, Michelle Letarte, Martin Post 10 11 , Isabella Caniggia 12 Journal Sci Rep Abstract Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a (show more...)Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a short form of the auxillary TGF-beta (TGFB) receptor endoglin (sENG). Until now, its release and functionality in PE remains poorly understood. Here we show that ENG selectively interacts with sphingomyelin(SM)-18:0 which promotes its clustering with metalloproteinase 14 (MMP14) in SM-18:0 enriched lipid rafts of the apical syncytial membranes from PE placenta where ENG is cleaved by MMP14 into sENG. The SM-18:0 enriched lipid rafts also contain type 1 and 2 TGFB receptors (TGFBR1 and TGFBR2), but not soluble fms-like tyrosine kinase 1 (sFLT1), another protein secreted in excess in the circulation of women with PE. The truncated ENG is then released into the maternal circulation via SM-18:0 enriched exosomes together with TGFBR1 and 2. Such an exosomal TGFB receptor complex could be functionally active and block the vascular effects of TGFB in the circulation of PE women. (hide) EV-METRIC 45% (78th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Blood plasma Sample origin pre-term birth Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture DG (d)(U)C Commercial method Protein markers EV: CD63/ PLAP/ sENG/ sFLT-1 non-EV: None Proteomics no EV density (g/ml) * Show all info Study aim Function Sample Species Homo sapiens Sample Type Blood plasma Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Equal to or above 150,000 g Pelleting performed Yes Pelleting: time(min) 1200 Pelleting: rotor type TLA-55 Pelleting: speed (g) 200000 Density gradient Type Discontinuous Number of initial discontinuous layers Not specified Lowest density fraction 0.25M Highest density fraction 2.5M Total gradient volume, incl. sample (mL) Not specified Sample volume (mL) Not spec Orientation Not specified Rotor type TLA-100 Speed (g) 110000 Duration (min) 1200 Fraction volume (mL) 10 fractions, 0.3mL per fraction Fraction processing None Commercial kit ExoQuick Characterization: Protein analysis Protein Concentration Method Not determined Western Blot Antibody details provided? No Detected EV-associated proteins CD63/ PLAP Not detected EV-associated proteins sENG/ sFLT-1 Flow cytometry Type of Flow cytometry Beckman Coulter Gallios 10/3 Antibody details provided? No Detected EV-associated proteins PLAP Characterization: Lipid analysis Lipi Characterization: Particle analysis NTA Report type Size range/distribution Reported size (nm) 100-400

	EV210220	6/6	Homo sapiens	Blood plasma	DG (d)(U)C ExoQuick Immunoaffinity capture	Ermini, Leonardo	2017	45%
Study summary Full title A Single Sphingomyelin Species Promotes Exosomal Release of Endoglin into the Maternal Circulation in Preeclampsia All authors Leonardo Ermini, Jonathan Ausman, Megan Melland-Smith, Behzad Yeganeh, Alessandro Rolfo, Michael L Litvack, Tullia Todros, Michelle Letarte, Martin Post 10 11 , Isabella Caniggia 12 Journal Sci Rep Abstract Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a (show more...)Preeclampsia (PE), an hypertensive disorder of pregnancy, exhibits increased circulating levels of a short form of the auxillary TGF-beta (TGFB) receptor endoglin (sENG). Until now, its release and functionality in PE remains poorly understood. Here we show that ENG selectively interacts with sphingomyelin(SM)-18:0 which promotes its clustering with metalloproteinase 14 (MMP14) in SM-18:0 enriched lipid rafts of the apical syncytial membranes from PE placenta where ENG is cleaved by MMP14 into sENG. The SM-18:0 enriched lipid rafts also contain type 1 and 2 TGFB receptors (TGFBR1 and TGFBR2), but not soluble fms-like tyrosine kinase 1 (sFLT1), another protein secreted in excess in the circulation of women with PE. The truncated ENG is then released into the maternal circulation via SM-18:0 enriched exosomes together with TGFBR1 and 2. Such an exosomal TGFB receptor complex could be functionally active and block the vascular effects of TGFB in the circulation of PE women. (hide) EV-METRIC 45% (78th percentile of all experiments on the same sample type) Reported Not reported Not applicable EV-enriched proteins Protein analysis: analysis of three or more EV-enriched proteins non EV-enriched protein Protein analysis: assessment of a non-EV-enriched protein qualitative and quantitative analysis Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected. electron microscopy images Particle analysis: inclusion of a widefield and close-up electron microscopy image density gradient Separation method: density gradient, at least as validation of results attributed to EVs EV density Separation method: reporting of obtained EV density ultracentrifugation specifics Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps antibody specifics Protein analysis: antibody clone/reference number and dilution lysate preparation Protein analysis: lysis buffer composition Study data Sample type Blood plasma Sample origin pre-term birth Focus vesicles exosome Separation protocol Separation protocol Gives a short, non-chronological overview of the different steps of the separation protocol. dUC = (Differential) (ultra)centrifugation DG = density gradient UF = ultrafiltration SEC = size-exclusion chromatography IAF = immuno-affinity capture DG (d)(U)C Commercial method Immunoaffinity capture Protein markers EV: CD63/ TGFBR1/ TGFBR2/ sENG non-EV: None Proteomics no EV density (g/ml) * Show all info Study aim Function Sample Species Homo sapiens Sample Type Blood plasma Separation Method (Differential) (ultra)centrifugation dUC: centrifugation steps Equal to or above 150,000 g Pelleting performed Yes Pelleting: time(min) 1200 Pelleting: rotor type TLA-55 Pelleting: speed (g) 200000 Density gradient Type Discontinuous Number of initial discontinuous layers Not specified Lowest density fraction 0.25M Highest density fraction 2.5M Total gradient volume, incl. sample (mL) Not specified Sample volume (mL) Not spec Orientation Not specified Rotor type TLA-100 Speed (g) 110000 Duration (min) 1200 Fraction volume (mL) 10 fractions, 0.3mL per fraction Fraction processing None Commercial kit ExoQuick Immunoaffinity capture Selected surface protein(s) PLAP Other Name other separation method Immunoaffinity capture Characterization: Protein analysis Protein Concentration Method Not determined Western Blot Antibody details provided? No Detected EV-associated proteins CD63/ TGFBR1/ TGFBR2 Not detected EV-associated proteins sENG Characterization: Lipid analysis Lipi Characterization: Particle analysis None

				1 - 6 of 6

EV-TRACK ID	EV210220
species	Homo sapiens
sample type	Blood plasma
condition	Healthy pregnant	Healthy pregnant	Preeclampsia	Preeclampsia	pre-term birth	pre-term birth
separation protocol	DG (d)(U)C ExoQuick	DG (d)(U)C ExoQuick IAF capture	DG (d)(U)C ExoQuick	DG (d)(U)C ExoQuick IAF capture	DG (d)(U)C ExoQuick	DG (d)(U)C ExoQuick IAF capture
Exp. nr.	1	2	3	4	5	6
EV-METRIC %	45	45	45	45	45	45